Health AI oversight dispute erupts between CHAI, U.S. officials
ILLINOIS, UNITED STATES — A fierce debate has broken out between the Coalition for Health AI (CHAI) and senior United States health officials, exposing deep divisions over who should shape the standards governing artificial intelligence in healthcare: the private sector, the federal government, or both, according to a report from Becker’s Health IT.
White House, HHS resist CHAI’s policy influence
The rift began when senior officials at the HHS and the White House accused CHAI of overstepping its role in healthcare AI policy. HHS Secretary Robert Kennedy Jr. publicly warned against allowing CHAI to “build a regulatory cartel,” in an October 8 post on X, backing an op-ed by Deputy HHS Secretary Jim O’Neill and FDA Commissioner Marty Makary that called for reducing federal barriers to AI innovation.
Founded in 2022, CHAI includes more than 3,000 members, including major technology firms such as Microsoft and leading health systems such as Mayo Clinic and Duke Health. The group has established assurance labs and worked with The Joint Commission to release AI guidance for clinical settings, a move some regulators say gives the group outsized influence in shaping de facto industry norms.
CHAI asserts transparency and collaborative mission
In a letter to members obtained by Becker’s, CHAI chief executive officer (CEO) Dr. Brian Anderson addressed the controversy directly, acknowledging “recent public attention on CHAI’s role and engagement with federal partners.”
He emphasized that the coalition “has no regulatory mission or role,” clarifying that its purpose is to “develop frameworks and best practices that reflect the consensus of that work in order to scale meaningful AI adoption and ensure better outcomes.”
Dr. Anderson added that CHAI’s efforts align with the AI action plan and the Executive Order on Removing Barriers to American Leadership in AI, which support innovation-friendly environments that often rely on outsourcing partnerships with technology firms and data specialists.
Such collaborations, he argued, allow hospitals and startups to access expertise they could not build in-house, an increasingly common model in healthcare AI development.
He also expressed willingness to engage with Mr. O’Neill’s office “to better understand any concerns” and to explore future cooperation “to accelerate the rapid innovation and development of health AI.”
While the debate underscores growing friction between regulators and private AI groups, it also highlights how outsourced AI development and data analytics are becoming central to the future of digital health, with questions of oversight and accountability now squarely in the public eye.
